Abiopharma

NASDAQ symbol attribute type Security_Name was changed. Previous value: Cidara Therapeutics, Inc. - Common Stock. New value: Cidara Therapeutics, Inc. - Common Stock.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: N. New value: Cidara Therapeutics, Inc. - Common Stock.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: N. New value: Salarius Pharmaceuticals, Inc. - Common Stock.

NASDAQ symbol attribute type Test_mode was changed. Previous value: N. New value: Salarius Pharmaceuticals, Inc. - Common Stock.

NASDAQ symbol attribute type Test_mode was changed. Previous value: N. New value: Cidara Therapeutics, Inc. - Common Stock.

NASDAQ symbol attribute type Security_Name was changed. Previous value: Salarius Pharmaceuticals, Inc. - Common Stock. New value: Salarius Pharmaceuticals, Inc. - Common Stock.

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference

InMode to Report Fourth Quarter & Full Year 2025 Financial Results and Hold Conference Call on February 10, 2026

AZN new Head of Investor Relations Joris Silon

Organon & Co. - Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

Request for Lifting of Trading Halt: Request for Lifting of Trading Halt

Final approval of ANDA #ANDA #216487 for CIPROFLOXACIN; DEXAMETHASONE. Decision date: 01/06/2026

Request for Trading Halt: Request for Trading Halt

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants